Holen Sie sich die Stockscreener-App
19.19
0.10%
-0.02
Handel nachbörslich:
19.19
Schlusskurs vom Vortag:
$19.21
Offen:
$19.41
24-Stunden-Volumen:
346.89K
Relative Volume:
0.63
Marktkapitalisierung:
$1.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.52M
KGV:
-8.6069
EPS:
-2.2296
Netto-Cashflow:
$-113.06M
1W Leistung:
+3.90%
1M Leistung:
+35.05%
6M Leistung:
+65.15%
1J Leistung:
+43.75%
1-Tages-Spanne:
$18.35
$19.90
1-Wochen-Bereich:
$17.62
$20.25
52-Wochen-Spanne:
$7.80
$20.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
19.19 | 1.24B | 0 | -121.52M | -113.06M | -2.2296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Eingeleitet | Citizens JMP | Mkt Perform |
| 2026-01-08 | Eingeleitet | BTIG Research | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Neutral |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference - Yahoo Finance
Bicara Therapeutics stock hits 52-week high at 19.72 USD By Investing.com - Investing.com Nigeria
Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (BCAX) Is Up 11.9% After US$172.5 Million Equity Raise And CEO Share Sale - simplywall.st
United StatesGoodwin Advises Bicara Therapeutics On Closing Of $172.5 Million Oversubscribed Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Bicara Therapeutics Inc. targets fibrotic tumor barriers in HPV negative R M HNSCC - Traders Union
Bicara Therapeutics stock hits 52-week high at 19.72 USD - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After FICERA Data And Capital Raise - Sahm
Stock Report: Can Bicara Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - Naître et grandir
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Bicara Therapeuti - GuruFocus
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock - Investing.com UK
Aug Sectors: How is Bicara Therapeutics Inc managing supply chain issuesMarket Volume Report & High Conviction Investment Ideas - baoquankhu1.vn
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Bicara Therapeutics Inc - GuruFocus
Fundamentals Check: How cyclical is Bicara Therapeutics Incs revenue streamWeekly Risk Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference - Yahoo Finance
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 16,300 Shares of Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $54,074.75 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 17,392 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 13,555 Shares - MarketBeat
Cohlhepp, Bicara Therapeutics president, sells $315k in shares By Investing.com - Investing.com Australia
Cohlhepp, Bicara Therapeutics president, sells $315k in shares - Investing.com South Africa
Bicara Therapeutics Inc builds enduring patient trust - Traders Union
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Bitget
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
BCAX (Nasdaq) insider sale: 16,300 shares via option exercise (03/04/2026) - Stock Titan
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug - simplywall.st
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BCAX (NASDAQ) insider to sell 13,555 shares after option exercise - Stock Titan
Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX) - Stock Titan
BCAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Bicara Therapeutics Inc benefit from rate cuts2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Chart Watch: Is Bicara Therapeutics Incs growth already priced inWeekly Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Major Insider Move Signals Growing Confidence in Bicara Therapeutics - TipRanks
Bicara Therapeutics (BCAX) stake reaches 11.5% at RA Capital group - Stock Titan
RA Capital funds boost Bicara Therapeutics (BCAX) stake with stock and warrants - Stock Titan
Assessing Bicara Therapeutics (BCAX) Valuation After Recent Share Price Moves And DCF Implied Upside - simplywall.st
Bicara Therapeutics (BCAX) President/COO sells 3,631 shares after option exercise - Stock Titan
Bicara Therapeutics closes $172.5 million stock offering By Investing.com - Investing.com India
Bicara Therapeutics Inc. closes oversubscribed equity offering to fund ficerafusp alfa advancement - Traders Union
Bicara Therapeutics Strengthens Finances with Equity Offering - TipRanks
Bicara Therapeutics closes $172.5 million stock offering - Investing.com South Africa
Bicara Therapeutics (NASDAQ: BCAX) raises $161.8M to fund ficerafusp alfa - Stock Titan
Bicara Therapeutics Announces Closing of Oversubscribed - GlobeNewswire
Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX - Defense World
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire | Chief Executive Officer |
Mar 09 '26 |
Sale |
19.17 |
36,766 |
704,657 |
339,392 |
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):